Contact us

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Speak to the team

"*" indicates required fields

DD slash MM slash YYYY

Where to find us

Sycamore House

16 Leyden Road

Stevenage, Hertfordshire

SG1 2BP

News Articles

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Making lung toxicity predictive, not reactive

This session highlighted where prediction fails today, the mechanistic gaps that limit current approaches, and how human NAMs can help close that gap. It also emphasised the key insights teams need to move from reactive findings to more proactive, informed decision-making.

De-risking nasal & pulmonary formulation development

To deliver therapeutics effectively to the nasal and pulmonary regions, developers must address the physiological barriers in these tissues. This webinar covers how formulation techniques and early in vitro toxicology work together to accelerate development and reduce risk.

Understanding off-target ADC lung toxicity: why human-relevant models matter

In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.

ImmuBYTES Session 3 Video Recording

DateCategory Watching Time 21 Minutes https://immuone.com/wp-content/uploads/2025/07/ImmuONE.mp4 Get in touch Add a Comment Related Posts

Looking beyond the baseline: new frontiers in lung and immune safety

In ImmuBYTES Session 3, “Looking Beyond Baseline Deviations for Lung and Immune Safety,” Prof. Victoria Hutter (CSO & Co-founder) highlighted how subtle changes in macrophage morphology can uncover early immune and lung effects.